C3.ai recently appointed Rob Schilling as Executive Vice President and Chief Commercial Officer, bringing his extensive experience in enterprise software sales to bolster the company’s commercial efforts. Over the past quarter, C3.ai’s share price rose 7%, a movement that aligns closely with the general market trend, which increased by 12% over the past year. This upward trajectory benefits from recent announcements such as the $13 million task order from the USAF and the expansion of their joint venture with Baker Hughes, both of which likely supported the company’s performance amidst these broader market conditions.
We’ve discovered 2 weaknesses for C3.ai (1 is concerning!) that you should be aware of before investing here.
Trump’s oil boom is here — pipelines are primed to profit. Discover the 22 US stocks riding the wave.
With C3.ai’s recent appointment of Rob Schilling as Executive Vice President and Chief Commercial Officer, there is potential for this leadership change to accelerate the company’s commercial success by harnessing Schilling’s extensive experience in enterprise software sales. Consequently, expanded partnerships with tech giants like Microsoft and AWS might bolster revenue, aiming at more consistent subscription revenue streams. However, despite recent gains, C3.ai’s performance over the last three years shows a total shareholder return of 35.79%. This compares to a one-year timeframe where the company underperformed against the broader US market’s 12.2% increase and also lagged behind the US Software industry, which returned 19.7%.
In terms of financial forecasts, the positive momentum does not offset ongoing challenges. Analysts predict continued revenue growth, driven by strategic alliances, but the company remains unprofitable, with earnings expected to stay negative in the short term. Additionally, the anticipated effect of the $13 million task order from the USAF and the Baker Hughes joint venture is factored into forecasts that might reduce the gap between current performance and the expected target. The current share price of US$22.51 remains a discount to the consensus analyst price target of US$29.47, indicating a potential 23.6% upside, but there’s notable skepticism among analysts about reaching these targets. Investors must weigh these prospects against the current operating losses and the long-term profitability outlook.
Click here and access our complete financial health analysis report to understand the dynamics of C3.ai.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Story Continues